Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
For the development of new treatment strategies against cancer, understanding signaling networks and their changes upon drug response is a promising approach to identify new drug targets and biomarker profiles. Pre‐requisites are tumor models with multiple read‐out options that accurately reflect the clinical situation. Tissue engineering technologies offer the integration of components of the tumor microenvironment which are known to impair drug response of cancer cells. We established three‐dimensional (3D) lung carcinoma models on a decellularized tissue matrix, providing a complex microenvironment for cell growth. For model generation, we used two cell lines with (HCC827) or without (A549) an activating mutation of the epidermal growth factor receptor (EGFR), exhibiting different sensitivities to the EGFR inhibitor gefitinib. EGFR activation in HCC827 was inhibited by gefitinib, resulting in a significant reduction of proliferation (Ki‐67 proliferation index) and in the induction of apoptosis (TUNEL staining, M30‐ELISA). No significant effect was observed in conventional cell culture. Results from the 3D model correlated with the results of an in silico model that integrates the EGFR signaling network according to clinical data. The application of TGFβ1 induced tumor cell invasion, accompanied by epithelial–mesenchymal transition (EMT) both in vitro and in silico. This was confirmed in the 3D model by acquisition of mesenchymal cell morphology and modified expression of fibronectin, E‐cadherin, β‐catenin and mucin‐1. Quantitative read‐outs for proliferation, apoptosis and invasion were established in the complex 3D tumor model. The combined in vitro and in silico model represents a powerful tool for systems analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Modeling Tissue Morphogenesis and Cancer in 3D
Yamada, K. M., & Cukierman, E. (2007) · Cell · doi:10.1016/j.cell.2007.08.006 · Cited by 1,751
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
Pao, W., & Chmielecki, J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2947 · Cited by 1,083
The Connectivity Map: A new tool for biomedical research
Lamb, J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2044 · Cited by 945 · cited 1×
“Drug responses do not mostly rely on a single specific target, but on multiple effects of this drug on the signaling network (Lamb, 2007).”
BackgroundKRAS Mutations in Non-Small Cell Lung Cancer
Riely, G. J., Marks, J., & Pao, W. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-107lc · Cited by 550
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
Sequist, L. V., Heist, R. S., Shaw, A. T., Fidias, P., Rosovsky, R., Temel, J. S., Lennes, I. T., Digumarthy, S., Waltman, B. A., Bast, E., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr489 · Cited by 370
Cited by
Hickman, J. A., Graeser, R., de Hoogt, R., Vidic, S., Brito, C., Gutekunst, M., van der Kuip, H., & IMI PREDECT consortium (2014) · Biotechnology Journal · doi:10.1002/biot.201300492 · Cited by 380
Three‑dimensional cell culture: A powerful tool in tumor research and drug discovery (Review)
Lv, D., Hu, Z., Lu, L., Lu, H., & Xu, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.7134 · Cited by 337
Scaffold-based 3D cell culture models in cancer research
Abuwatfa, W. H., Pitt, W. G., & Husseini, G. A. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00994-y · Cited by 324
Organ-on-chip models of cancer metastasis for future personalized medicine: From chip to the patient
Caballero, D., Kaushik, S., Correlo, V. M., Oliveira, J. M., Reis, R. L., & Kundu, S. C. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.005 · Cited by 221
Wallstabe, L., Göttlich, C., Nelke, L. C., Kühnemundt, J., Schwarz, T., Nerreter, T., Einsele, H., Walles, H., Dandekar, G., Nietzer, S. L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126345 · Cited by 193
“primary lung carcinomas, and recapitulated ‘real-life’ pathophysiologic features including growth kinetic, tumor cell migration and invasion, and epithelial-to-mesenchymal transition after stimulation with TGF-β1 (13, 14).”
Self-citation
Metadata
- Authors
- Stratmann, A. T., Fecher, D., Wangorsch, G., Göttlich, C., Walles, T., Walles, H., Dandekar, T., Dandekar, G., & Nietzer, S. L.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2013-12-18
- Volume
- 8
- Issue
- 2
- Pages
- 351-365
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2035954579
- Cited by
- 86
- References
- 6
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model. https://app.cochat.ai/papers/10.1016/j.molonc.2013.11.009
- The paper
- Stratmann, A. T., Fecher, D., Wangorsch, G., Göttlich, C., Walles, T., Walles, H., Dandekar, T., Dandekar, G., & Nietzer, S. L. (2014). Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model. Molecular Oncology. https://doi.org/10.1016/j.molonc.2013.11.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.